These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 12532428)

  • 1. Comparison of antiangiogenic activities using paclitaxel (taxol) and docetaxel (taxotere).
    Grant DS; Williams TL; Zahaczewsky M; Dicker AP
    Int J Cancer; 2003 Mar; 104(1):121-9. PubMed ID: 12532428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of endothelial cell function in vitro and angiogenesis in vivo by docetaxel (Taxotere): association with impaired repositioning of the microtubule organizing center.
    Hotchkiss KA; Ashton AW; Mahmood R; Russell RG; Sparano JA; Schwartz EL
    Mol Cancer Ther; 2002 Nov; 1(13):1191-200. PubMed ID: 12479700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiangiogenic and antitumor activity of IDN 5390, a new taxane derivative.
    Taraboletti G; Micheletti G; Rieppi M; Poli M; Turatto M; Rossi C; Borsotti P; Roccabianca P; Scanziani E; Nicoletti MI; Bombardelli E; Morazzoni P; Riva A; Giavazzi R
    Clin Cancer Res; 2002 Apr; 8(4):1182-8. PubMed ID: 11948131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Docetaxel versus paclitaxel for antiangiogenesis.
    Vacca A; Ribatti D; Iurlaro M; Merchionne F; Nico B; Ria R; Dammacco F
    J Hematother Stem Cell Res; 2002 Feb; 11(1):103-18. PubMed ID: 11847007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative antitumor efficacy of docetaxel and paclitaxel in nude mice bearing human tumor xenografts that overexpress the multidrug resistance protein (MRP).
    Vanhoefer U; Cao S; Harstrick A; Seeber S; Rustum YM
    Ann Oncol; 1997 Dec; 8(12):1221-8. PubMed ID: 9496387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors.
    Sweeney CJ; Miller KD; Sissons SE; Nozaki S; Heilman DK; Shen J; Sledge GW
    Cancer Res; 2001 Apr; 61(8):3369-72. PubMed ID: 11309294
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of antitumour effects of docetaxel (Taxotere) on human gastric cancers in vitro and in vivo.
    Tanaka M; Obata T; Sasaki T
    Eur J Cancer; 1996 Feb; 32A(2):226-30. PubMed ID: 8664032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Taxane-mediated antiangiogenesis in vitro: influence of formulation vehicles and binding proteins.
    Ng SS; Figg WD; Sparreboom A
    Cancer Res; 2004 Feb; 64(3):821-4. PubMed ID: 14871806
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The farnesyl protein transferase inhibitor SCH66336 synergizes with taxanes in vitro and enhances their antitumor activity in vivo.
    Shi B; Yaremko B; Hajian G; Terracina G; Bishop WR; Liu M; Nielsen LL
    Cancer Chemother Pharmacol; 2000; 46(5):387-93. PubMed ID: 11127943
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of growth and metastasis of orthotopic human prostate cancer in athymic mice by combination therapy with pegylated interferon-alpha-2b and docetaxel.
    Huang SF; Kim SJ; Lee AT; Karashima T; Bucana C; Kedar D; Sweeney P; Mian B; Fan D; Shepherd D; Fidler IJ; Dinney CP; Killion JJ
    Cancer Res; 2002 Oct; 62(20):5720-6. PubMed ID: 12384530
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Inhibition of tumor neo-angiogenesis and induction of apoptosis as properties of docetaxel (taxotere)].
    Schimming R; Hunter NR; Mason KA; Milas L
    Mund Kiefer Gesichtschir; 1999 Jul; 3(4):210-2. PubMed ID: 10474267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibitory effects of artesunate on angiogenesis and on expressions of vascular endothelial growth factor and VEGF receptor KDR/flk-1.
    Chen HH; Zhou HJ; Wu GD; Lou XE
    Pharmacology; 2004 May; 71(1):1-9. PubMed ID: 15051917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Docetaxel enhances the therapeutic effect of the angiogenesis inhibitor TNP-470 (AGM-1470) in metastatic human transitional cell carcinoma.
    Inoue K; Chikazawa M; Fukata S; Yoshikawa C; Shuin T
    Clin Cancer Res; 2003 Feb; 9(2):886-99. PubMed ID: 12576464
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
    Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The chemopreventive agent oltipraz possesses potent antiangiogenic activity in vitro, ex vivo, and in vivo and inhibits tumor xenograft growth.
    Ruggeri BA; Robinson C; Angeles T; Wilkinson J; Clapper ML
    Clin Cancer Res; 2002 Jan; 8(1):267-74. PubMed ID: 11801568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metronomic docetaxel chemotherapy inhibits angiogenesis and tumor growth in a gastric cancer model.
    Wu H; Xin Y; Zhao J; Sun D; Li W; Hu Y; Wang S
    Cancer Chemother Pharmacol; 2011 Oct; 68(4):879-87. PubMed ID: 21290245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paclitaxel (Taxol) and docetaxel (Taxotere): not simply two of a kind.
    Verweij J; Clavel M; Chevalier B
    Ann Oncol; 1994 Jul; 5(6):495-505. PubMed ID: 7918121
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumor efficacy of taxane liposomes on a human ovarian tumor xenograft in nude athymic mice.
    Sharma A; Straubinger RM; Ojima I; Bernacki RJ
    J Pharm Sci; 1995 Dec; 84(12):1400-4. PubMed ID: 8748320
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined therapy with direct and indirect angiogenesis inhibition results in enhanced antiangiogenic and antitumor effects.
    Abdollahi A; Lipson KE; Sckell A; Zieher H; Klenke F; Poerschke D; Roth A; Han X; Krix M; Bischof M; Hahnfeldt P; Grone HJ; Debus J; Hlatky L; Huber PE
    Cancer Res; 2003 Dec; 63(24):8890-8. PubMed ID: 14695206
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential antagonism of tubulin-binding anticancer agents in combination therapies.
    Taraboletti G; Micheletti G; Dossi R; Borsotti P; Martinelli M; Fiordaliso F; Ryan AJ; Giavazzi R
    Clin Cancer Res; 2005 Apr; 11(7):2720-6. PubMed ID: 15814654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.